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EDITORIAL
Obstructive nephropathy and the developing kidney: Too little
or too much angiotensin?
Although obstructive nephropathy remains a major
cause of renal insufficiency in infants and children, cur-
rent medical and surgical management is unsatisfactory.
The response of the developing kidney to obstructed
urine flow depends on the stage of renal development,
and the severity of obstruction: obstruction early in
nephrogenesis may lead to renal dysplasia, while obstruc-
tion later in nephrogenesis delays nephron maturation,
and can result in reduced nephron number. In contrast to
the adult, who can recover from even complete ureteral
obstruction, the fetus and neonate are uniquely vulner-
able; permanent sequelae may result despite the release
of only several days of ureteral obstruction. Following
the completion of nephrogenesis in normal development,
structural and functional nephron maturation continues.
While nephrogenesis is complete before birth in man and
guinea pig, nephrogenesis continues 10 days after birth in
the rat and mouse. Renal development at the time of birth
in the rat and mouse is, therefore, analogous to that of the
midtrimester human fetus, while renal maturation in the
14-day-old rat is analogous to that of the human infant.
We have reported that in rats, three months following the
relief of complete unilateral ureteral obstruction (UUO)
from 14 to 19 days of age, renal growth is impaired, and
nephron number is reduced [1].
Most cases of congenital clinical UUO are caused by
partial ureteropelvic junction obstruction resulting from
maldevelopment of the urinary tract. In this issue of Kid-
ney International, Beharrie et al [2] describe an experi-
mental model of partial UUO in the weanling rat, and the
effects of angiotensin-converting enzyme inhibition over
a 21-day period. The intrarenal renin-angiotensin system
is markedly activated by UUO in early maturation, and
inhibition of angiotensin has been shown to reduce renal
injury and to preserve renal function in the neonatal rat,
mouse, and guinea pig subjected to urinary tract obstruc-
tion [3]. There is also clinical evidence of activation of the
renin-angiotensin system in infants with congenital UUO,
with angiotensin-dependent renal vasoconstriction pro-
portional to the severity of obstruction [4].
In their experimental model of partial UUO in the
weanling rat, Beharrie et al [2] report the development of
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significant proteinuria from the obstructed kidney, which
is entirely suppressed by the administration of enalapril.
This suggests that UUO causes early glomerular injury in
addition to tubular dysfunction (evidenced by decreased
uric acid excretion and increased solute excretion). In
neonatal mice with variable expression of functional an-
giotensinogen genes, renal interstitial fibrosis resulting
from chronic complete UUO is reduced in parallel with
the reduction in angiotensinogen expression [5]. Because
proteinuria itself may aggravate tubulointersitial disease
by inducing tubular apoptosis [6], the salutary impact of
enalapril on obstructive nephropathy may extend beyond
its antifibrotic effects. An additional benefit of enalapril
in this model of partial UUO is a shifting of the renal so-
lute load from the obstructed to the contralateral kidney:
this could reduce tubular dilatation, and thereby decrease
tubular axial strain and apoptosis (a major contributor to
tubular atrophy in the hydronephrotic kidney) [7].
It is becoming increasingly clear that major inde-
pendent determinants of progression of congenital re-
nal disorders include hypertension, proteinuria, and the
endogenous activity of the renin-angiotensin system [8,
9]. Children with the DD polymorphism of angiotensin-
converting enzyme have a significantly more rapid pro-
gression to renal insufficiency, presumably due to greater
intrarenal generation of angiotensin [9]. Chronic ad-
ministration of angiotensin-converting enzyme inhibitors
is therefore particularly attractive, since the vascular,
glomerular, tubular, and interstitial lesions of obstruc-
tive nephropathy all appear to be significantly mediated
or modulated by angiotensin. In addition, as reported
by Beharrie et al [2], rats with partial UUO had elevated
serum uric acid levels that were normalized by the admin-
istration of enalapril (which doubled uric acid clearance).
As pointed out by the authors, however, caution
must be exercised in blocking the endogenous renin-
angiotensin system of the developing kidney because
normal renal development and maturation are depen-
dent on it. Angiotensin inhibition in postnatal rats during
the period of nephrogenesis results in renal vascular
and tubular abnormalities, and decreased expression
of critical growth factors [10, 11]. Mice lacking func-
tional angiotensin type 1 receptors actually develop a
hydronephrotic phenotype, with renal pelvic dilatation,
papillary hypoplasia, and interstitial macrophage infil-
tration and fibrosis [12]. Moreover, loss of function of the
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angiotensin type 2 receptor is associated with a variety
of urinary tract malformations, including obstructive
nephropathy [13]. Thus, too little angiotensin during re-
nal embryogenesis may be as harmful as too much
angiotensin during the evolution of obstructive
nephropathy. Additional studies will be required to
define the cellular mechanisms underlying these con-
trasting salutary and injurious roles for angiotensin in
the maturing hydronephrotic kidney.
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